Department of Neurosurgery, University Hospital, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
Curr Oncol. 2024 Jul 19;31(7):4079-4092. doi: 10.3390/curroncol31070304.
Intradural spinal metastases are considered rare. At present, limited information is available on incidence, surgical management, and outcomes.
We conducted a retrospective patient chart review from 2002 to 2024, identifying all patients surgically treated for intradural spinal metastases. Clinical, surgical and survival data were collected and compared to literature data for patients surgically treated for extradural spinal metastases.
A total of 172 patients with spinal metastases were identified with 13 patients meeting inclusion criteria (7.6%). The mean age at diagnosis of intradural spinal metastases was 52 ± 22 years, with diverse primaries including lung ( = 3), breast ( = 2), sarcoma ( = 2), and six unique entities. Intradural spinal metastasis was diagnosed on average of 3.3 years after primary diagnosis. In total, we observed five (38%) intradural-extramedullary and eight (62%) intramedullary metastases, located in the cervical (38.5%), thoracic (46.1%) and lumbar spine (15.4%). The most common preoperative symptoms were pain, sensory changes, and gait ataxia (each 76.9%). Gross total resection was achieved in 54%, and local tumor control in 85%. Postoperatively, 92% exhibited clinical improvement or stability. Most frequent adjuvant treatment was radio- and/or chemotherapy in 85%. The average survival after operation for spinal intradural metastases was 5 months, ranging from 1 month to 120 months. The location of the intradural metastasis in the cervical spine was associated with a significantly more favorable survival outcome (compared to thoracic/lumbar location, = 0.02).
Intradural location of spinal metastases is rare (7.6%). Even so, surgical resection is safe and effective for neurological improvement, and survival appears lower compared to the reported survival of extradural spinal metastases.
硬脊膜内脊髓转移瘤被认为较为罕见。目前,有关其发病率、手术治疗及预后的信息有限。
我们对 2002 年至 2024 年的患者病历进行了回顾性分析,确定了所有接受硬脊膜内脊髓转移瘤手术治疗的患者。收集了临床、手术和生存数据,并与接受硬脊膜外脊髓转移瘤手术治疗的患者的文献数据进行了比较。
共确定了 172 例脊髓转移瘤患者,其中 13 例符合纳入标准(7.6%)。硬脊膜内脊髓转移瘤的诊断年龄平均为 52±22 岁,原发灶多样,包括肺癌(3 例)、乳腺癌(2 例)、肉瘤(2 例)和 6 种独特实体瘤。硬脊膜内脊髓转移瘤平均在原发性疾病诊断后 3.3 年被诊断。共有 5 例(38%)为硬脊膜外-髓内转移,8 例(62%)为髓内转移,位于颈椎(38.5%)、胸椎(46.1%)和腰椎(15.4%)。最常见的术前症状是疼痛、感觉改变和步态共济失调(各占 76.9%)。大体全切除率为 54%,局部肿瘤控制率为 85%。术后 92%的患者临床症状改善或稳定。最常见的辅助治疗是放疗和/或化疗(85%)。硬脊膜内脊髓转移瘤术后平均生存时间为 5 个月,范围为 1 个月至 120 个月。硬脊膜内转移瘤位于颈椎与位于胸腰椎的相比,生存结局显著更优( = 0.02)。
硬脊膜内脊髓转移瘤的发生率较低(7.6%)。即便如此,手术切除对改善神经功能和提高生存率是安全有效的,与硬脊膜外脊髓转移瘤的报道生存率相比,硬脊膜内转移瘤的生存率似乎较低。